Medicare Coverage for Parkinson's Disease: 2025 Guide
Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's, affecting approximately 1 million Americans. Most people with Parkinson's are diagnosed after age 60, making Medicare the primary insurer for the majority of patients. Medicare covers medications, specialist care, therapies, deep brain stimulation surgery, and home health — but Parkinson's is a progressive disease, and planning ahead for increasing care needs is essential.
Parkinson's Disease Coverage Quick Reference
| Service | Part | Your Cost (2025) | Notes |
|---|---|---|---|
| Neurologist visits | Part B | 20% after $257 deductible | Movement disorder specialist strongly recommended |
| MRI / DaTscan (dopamine imaging) | Part B | 20% after deductible | DaTscan covered for diagnosis when clinical picture uncertain |
| Levodopa/carbidopa (Sinemet) | Part D | Tier 1 (generic); very low cost | Foundation of PD treatment; inexpensive generic |
| Extended-release levodopa (Rytary) | Part D | Tier 3–4; check plan | Brand; generic levodopa/carbidopa ER also available |
| MAO-B inhibitors (selegiline, rasagiline, safinamide) | Part D | Tier 1–2 (selegiline generic); Tier 3 (Xadago) | Adjunct therapy; selegiline is very inexpensive generic |
| COMT inhibitors (entacapone, tolcapone) | Part D | Tier 1–2 (generics) | For motor fluctuations; extend levodopa effect |
| Dopamine agonists (ropinirole, pramipexole) | Part D | Tier 1 (generics) | Monotherapy or adjunct; inexpensive generics |
| Rotigotine patch (Neupro) | Part D | Tier 3–4; check plan | Transdermal dopamine agonist; 24-hour delivery |
| Apomorphine injection (Apokyn) | Part D or Part B | Varies; Part D OOP cap $2,000 | Rescue therapy for "off" episodes |
| Levodopa-carbidopa intestinal gel (Duopa) | Part B (physician-administered) | 20% after deductible | Continuous intestinal infusion for advanced PD; Part B covers pump |
| Deep brain stimulation (DBS) surgery | Part A | $1,676 deductible per benefit period | Major inpatient surgery; highly effective for motor symptoms |
| DBS device and programming follow-up | Part B | 20% after deductible | Regular programming visits; device battery replacement (Part A) |
| Focused ultrasound (MRI-guided) | Part B | 20% after deductible | For tremor-dominant PD; non-invasive thalamotomy; coverage varies |
| Physical therapy | Part B | 20% after deductible | Gait training, balance, fall prevention; LSVT BIG protocol covered |
| Speech-language pathology | Part B | 20% after deductible | LSVT LOUD protocol; swallowing evaluation (modified barium swallow) |
| Occupational therapy | Part B | 20% after deductible | ADL training, adaptive equipment, home safety assessment |
| Home health (skilled) | Part A/B | $0 for covered services | PT, OT, SLP in home when homebound; requires skilled care order |
| Walker, cane, wheelchair | Part B (DME) | 20% after deductible | As mobility needs evolve; requires physician order |
| Hospital bed, grab bars (safety equipment) | Part B (DME) | 20% after deductible | Hospital bed covered; grab bars typically not covered |
| Swallowing evaluation (videofluoroscopy) | Part B | 20% after deductible | For dysphagia — common in advanced PD |
Medications: A Strong Generic Foundation
The cornerstone of Parkinson's treatment — levodopa/carbidopa (Sinemet) — has been generic for decades and is among the least expensive drugs in Medicare Part D, typically $5–$15/month. Most first-line and adjunct Parkinson's medications have generic versions:
- Levodopa/carbidopa (generic Sinemet): Tier 1 — often $3–$10/month
- Ropinirole (generic Requip): Tier 1 — $5–$12/month
- Pramipexole (generic Mirapex): Tier 1 — $5–$12/month
- Selegiline (generic): Tier 1 — very inexpensive
- Entacapone (generic Comtan): Tier 1–2
- Amantadine (generic): Tier 1 — used for dyskinesias
Newer formulations (Rytary, Xadago, Nourianz) remain brand-only and are Tier 3–4. The 2025 $2,000 Part D OOP cap limits your maximum exposure on these more expensive options.
Deep Brain Stimulation (DBS): Medicare Coverage
Deep brain stimulation is a surgical procedure in which electrodes are implanted in specific brain regions (typically the subthalamic nucleus or globus pallidus) to modulate abnormal electrical activity. It is among the most effective treatments for motor symptoms of Parkinson's disease.
Medicare covers DBS when:
- Diagnosis of idiopathic Parkinson's disease (not atypical parkinsonism)
- Adequate trial of medications (levodopa-responsive symptoms)
- Disabling motor fluctuations or dyskinesias despite optimal medication
- Performed at a Medicare-approved facility by a qualified neurosurgeon
The surgery itself is covered under Part A (inpatient hospitalization, $1,676 deductible per benefit period). The DBS programmer/controller device is covered. Follow-up programming visits are covered under Part B at 20% coinsurance. Battery replacement surgery (typically every 3–5 years) is also covered under Part A.
Medigap Plan G covers the Part A deductible and the 20% Part B coinsurance on programming visits.
LSVT: The Specialized Parkinson's Therapy Protocols
Two evidence-based, Parkinson's-specific therapy protocols are covered under Medicare:
LSVT LOUD (Speech Therapy)
Lee Silverman Voice Treatment (LSVT LOUD) is an intensive speech therapy protocol specifically designed for Parkinson's hypophonia (soft voice) and dysarthria. It involves 16 sessions over 4 weeks. Medicare covers LSVT LOUD under Part B speech-language pathology benefit (20% coinsurance). Research shows 80-90% of patients improve voice loudness significantly.
LSVT BIG (Physical Therapy)
LSVT BIG is an intensive physical therapy protocol that retrains movement amplitude in Parkinson's patients (combating the tendency toward small, shuffling movements). Also 16 sessions over 4 weeks. Covered under Part B physical therapy benefit at 20% coinsurance.
Both protocols can be repeated as the disease progresses. Ask your neurologist for a referral to an LSVT-certified therapist.
Swallowing Problems: Dysphagia Coverage
Dysphagia (difficulty swallowing) affects up to 80% of people with advanced Parkinson's disease and is a major cause of aspiration pneumonia — the leading cause of death in Parkinson's. Medicare covers:
- Speech-language pathology evaluation and treatment for dysphagia
- Modified barium swallow study / videofluoroscopic swallowing study (VFSS) — covered under Part B
- Fiberoptic endoscopic evaluation of swallowing (FEES) — covered
- Dietary modification counseling
If dysphagia becomes severe enough that oral feeding is unsafe, Medicare may cover enteral nutrition (tube feeding) through a PEG tube as DME — a difficult but sometimes necessary step in advanced disease.
Home Health and the Homebound Requirement
As Parkinson's progresses and mobility becomes more limited, home health coverage becomes increasingly important. Medicare covers home health when:
- You are homebound (leaving home requires considerable effort and is infrequent)
- A physician orders skilled care
- A Medicare-certified home health agency provides the services
Covered home health services for Parkinson's patients include: skilled nursing visits, physical therapy, occupational therapy, and speech-language pathology. Home health aide services are covered when skilled care is also being provided simultaneously.
Home health is covered at $0 cost-sharing for covered services — one of Medicare's most valuable benefits for homebound patients.
Frequently Asked Questions
Yes. Medicare covers deep brain stimulation (DBS) surgery for Parkinson's disease patients who have levodopa-responsive symptoms and are experiencing disabling motor fluctuations or dyskinesias despite optimal medication management. The implantation surgery is covered under Part A (inpatient), with the $1,676 Part A deductible. Follow-up programming visits are covered under Part B at 20% coinsurance. Medigap Plan G covers both. The procedure must be performed at a qualified center by a credentialed neurosurgeon.
Yes. All Parkinson's medications are covered under Medicare Part D. The most commonly used drugs — levodopa/carbidopa, ropinirole, pramipexole, selegiline, entacapone — are available as generics and cost just $5–$15/month on most Part D plans. Newer brand-name formulations like Rytary are Tier 3–4 but subject to the 2025 $2,000 Part D out-of-pocket cap. Compare Part D plans during the Annual Election Period if you're on a brand-name Parkinson's medication.
Yes. Medicare Part B covers speech-language pathology for Parkinson's-related voice and speech problems, including the LSVT LOUD protocol — an intensive 16-session program proven to significantly improve voice loudness and clarity. You pay 20% coinsurance after the Part B deductible. Medigap Plan G covers that 20%. Speech therapy also covers swallowing evaluation and treatment (dysphagia), which is critical for Parkinson's patients as the disease progresses. There is no hard annual session limit — coverage continues as long as therapy is medically necessary and showing benefit.